Pfizer drug offers strong protection from Covid hospitalisation or death, data confirm

Pfizer’s Covid-19 antiviral pill cuts the risk of hospitalisation or death by up to 89 per cent in high-risk patients, according to final trial results that confirm earlier data.

The drug candidate, known as Paxlovid, also cuts the risk of hospitalisation and death for standard-risk patients by 70 per cent. The drug works best if first given within three days of the onset of symptoms but is still 88 per cent effective in high-risk patients within five days.

The results come after Merck was forced to revise down the efficacy rate for its antiviral from 50 per cent to 30 per cent. While the UK has approved the Merck pill, the US regulator has yet to make a decision, after scientific advisers only narrowly voted in favour of it.

Albert Bourla, Pfizer’s chief executive, said its data was “further corroboration” that the antiviral candidate would have a “meaningful impact on the lives of many”.

“Emerging variants of concern, like Omicron, have exacerbated the need for accessible treatment options for those who contract the virus, and we are confident that, if authorised or approved, this potential treatment could be a critical tool to help quell the pandemic,” he said.

Pfizer believes the antiviral is likely to retain its ability to tackle the Omicron variant of coronavirus, as it has been able to address previous variants including Delta. An early lab study showed it continued to work against Omicron, and other studies are under way.

The US drugmaker, which is still in the process of ramping up production, has said it will have only 180,000 courses available this year. It has raised its target for next year to 80m courses.

The final data on high-risk patients showed that out of 697 people given Paxlovid, only five were hospitalised and none died. In contrast, 44 of the patients given a placebo were hospitalised and nine died.

In an interim analysis for standard-risk patients, two out of the 333 who received the drug were hospitalised, compared with eight in the placebo arm. There were no deaths in either of the trial arms.

However, the trials included only unvaccinated participants, so there is no data on the degree to which the drugs reduce the risk for vaccinated patients, who already have a lower risk of severe disease.